Andrew Z. Fenves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Z. Fenves has a total of 256 co-authors. Here are the top co-authors by number of shared publications:
Michael Emmett
B Department of Internal Medicine , Baylor University Medical Center , Dallas , TX , USA
4 shared publicationsMarvin J. Stone
3 shared publications- Amulya Nagarur
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
2 shared publications - Ajay K. Israni
Renal-Electrolyte & Hypertension Division, Department of Medicine, University of Pennsylvania School of Medicine, Pennsylvania, USA
1 shared publication Alain Bonnardeaux
1 shared publication- Alan David Salama
University College London
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (9) , 573
Gastric Bypass Associated Hyperammonemia (GaBHA): A Case Study, Scoping Review of the Literature, and Proposed New Pathophysiologic Mechanism
Background/Objectives: GaBHA syndrome (gastric bypass hyperammonemia) is an emerging new syndrome primarily in women who had prior Roux-en-Y gastric bypass surgery (RYGB) and then developed non-cirrhotic hyperammonemia with a high case–fatality ratio. Genetic and nutritional deficiencies have been implicated in the pathogenesis of this clinical condition, but none has been proven. We present an illustrative case and do a scoping review of the current literature in 58 patients with this diagnosis. Methods: A retrospective scoping literature review was utilized to identify patients who fulfilled 1. RYGB surgery, and 2. Hyperammonemic encephalopathy following the PRISMA extended checklist. We searched PubMed, MedLine, SCOPUS, and Web of Science databases. Results: We described the classic presenting symptoms and laboratory findings of this syndrome. We confirmed the female predominance (93%) and the high case–fatality ratio (32%). We then presented a novel hypothesis contending that arginine deficiency ultimately leads to a functional deficiency of the ornithine transcarbamolyase (OTC) enzyme, leading to the non-cirrhotic life-threatening hyperammonemia. Our hypothesis may also explain the high incidence of hypoglycemia found in these patients as we found in our search. Our proposed hypothesis may also be relevant to the occurrence of hyperammonemia in some solid organ transplant recipients. Conclusions: GaBHA syndrome is emerging as an important potential adverse outcome after RYGB surgery. It has a female predominance and a high case–fatality ratio. Arginine deficiency may explain the emergence of a functional OTC deficiency, which then leads to the severe hyperammonemia, and may also explain the frequent occurrence of hypo-glycemia in these patients.
- 27 August 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (9) , 573
Open AccessGastric Bypass Associated Hyperammonemia (GaBHA): A Case Study, Scoping Review of the Literature, and Proposed New Pathophysiologic Mechanism
Background/Objectives: GaBHA syndrome (gastric bypass hyperammonemia) is an emerging new syndrome primarily in women who had prior Roux-en-Y gastric bypass surgery (RYGB) and then developed non-cirrhotic hyperammonemia with a high case–fatality ratio. Genetic and nutritional deficiencies have been implicated in the pathogenesis of this clinical condition, but none has been proven. We present an illustrative case and do a scoping review of the current literature in 58 patients with this diagnosis. Methods: A retrospective scoping literature review was utilized to identify patients who fulfilled 1. RYGB surgery, and 2. Hyperammonemic encephalopathy following the PRISMA extended checklist. We searched PubMed, MedLine, SCOPUS, and Web of Science databases. Results: We described the classic presenting symptoms and laboratory findings of this syndrome. We confirmed the female predominance (93%) and the high case–fatality ratio (32%). We then presented a novel hypothesis contending that arginine deficiency ultimately leads to a functional deficiency of the ornithine transcarbamolyase (OTC) enzyme, leading to the non-cirrhotic life-threatening hyperammonemia. Our hypothesis may also explain the high incidence of hypoglycemia found in these patients as we found in our search. Our proposed hypothesis may also be relevant to the occurrence of hyperammonemia in some solid organ transplant recipients. Conclusions: GaBHA syndrome is emerging as an important potential adverse outcome after RYGB surgery. It has a female predominance and a high case–fatality ratio. Arginine deficiency may explain the emergence of a functional OTC deficiency, which then leads to the severe hyperammonemia, and may also explain the frequent occurrence of hypo-glycemia in these patients.
- Open Access
- 20 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1273-1275
Physiologic Solutions are Superior to Normal Saline in Critically Ill Patients: CON
An abstract is unavailable. This article is available as a PDF only.
- 20 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1273-1275
Open AccessPhysiologic Solutions are Superior to Normal Saline in Critically Ill Patients: CON
An abstract is unavailable. This article is available as a PDF only.
- 1 June 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (6) , 777-778
Fractional Excretion of Sodium (FENa)
- 1 June 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (6) , 777-778
Fractional Excretion of Sodium (FENa)
- 26 February 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (4) , 481-483
Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin
We describe a 68-year-old man who presented with progressive weakness in proximal muscles of all four limbs and was found to have autoantibody-negative necrotizing autoimmune myopathy (NAM). His myopathy was refractory to corticosteroids and methotrexate, but subsequently demonstrated successful response to intravenous immunoglobulin (IVIG). The patient also received rituximab, but the timing of his recovery favored IVIG as the more important factor in terms of efficacy. Treatment guidelines for seronegative necrotizing myopathies are lacking. This case suggests a potential efficacious treatment option for the seronegative subset of NAM.
- 26 February 2021
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (4) , 481-483
Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin
We describe a 68-year-old man who presented with progressive weakness in proximal muscles of all four limbs and was found to have autoantibody-negative necrotizing autoimmune myopathy (NAM). His myopathy was refractory to corticosteroids and methotrexate, but subsequently demonstrated successful response to intravenous immunoglobulin (IVIG). The patient also received rituximab, but the timing of his recovery favored IVIG as the more important factor in terms of efficacy. Treatment guidelines for seronegative necrotizing myopathies are lacking. This case suggests a potential efficacious treatment option for the seronegative subset of NAM.
- 27 February 2020
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 33 (2) , 191-194
Evaluation of the use of erythropoietin-stimulating agents in a hospital setting to assess the necessity of a protocol-driven anemia management service
Erythropoietin-stimulating agents (ESA) have revolutionized the management of anemia. However, these agents are not always utilized with proper monitoring parameters, which can present significant safety concerns, unwarranted drug expenditures, and decreased ESA efficacy. This retrospective study assessed the utilization of all ESAs in non–intensive care unit hospitalized patients at a large academic medical center from August 18, 2018, to August 31, 2018, using established guideline-based assessment criteria. Among the 167 doses of ESA evaluated, 86% (n = 144) were utilized in accordance with guideline-based assessment criteria regarding laboratory monitoring of iron studies. However, 24% (n = 40) of ESA doses were administered to patients with active, untreated iron deficiency at the time of administration. Although most ESA doses were utilized in accordance with the guideline-based criteria, interventions can be implemented to further improve anemia treatment. Implementing a protocol-driven anemia management service is one strategy that can improve patient care, advance patient safety, and be cost-beneficial.
- 27 February 2020
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 33 (2) , 191-194
Evaluation of the use of erythropoietin-stimulating agents in a hospital setting to assess the necessity of a protocol-driven anemia management service
Erythropoietin-stimulating agents (ESA) have revolutionized the management of anemia. However, these agents are not always utilized with proper monitoring parameters, which can present significant safety concerns, unwarranted drug expenditures, and decreased ESA efficacy. This retrospective study assessed the utilization of all ESAs in non–intensive care unit hospitalized patients at a large academic medical center from August 18, 2018, to August 31, 2018, using established guideline-based assessment criteria. Among the 167 doses of ESA evaluated, 86% (n = 144) were utilized in accordance with guideline-based assessment criteria regarding laboratory monitoring of iron studies. However, 24% (n = 40) of ESA doses were administered to patients with active, untreated iron deficiency at the time of administration. Although most ESA doses were utilized in accordance with the guideline-based criteria, interventions can be implemented to further improve anemia treatment. Implementing a protocol-driven anemia management service is one strategy that can improve patient care, advance patient safety, and be cost-beneficial.
- 23 December 2019
- Published by Springer Nature in Obesity Surgery
- Vol. 30 (3) , 1138-1139
Letter to the Editor Responding to “Recurrent Hyperammonemia During Enteral Tube Feeding for Severe Protein Malnutrition After Bariatric Surgery.”
- 23 December 2019
- Published by Springer Nature in Obesity Surgery
- Vol. 30 (3) , 1138-1139
Letter to the Editor Responding to “Recurrent Hyperammonemia During Enteral Tube Feeding for Severe Protein Malnutrition After Bariatric Surgery.”
- 1 October 2019
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 27 (10) , 1454-1461
Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study
- 1 October 2019
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 27 (10) , 1454-1461
Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study
- 2 January 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (1) , 131-133
Spontaneous bleeding in a patient on enoxaparin with poor renal function
Creatinine-based equations are used as standard ways to estimate glomerular filtration rate and kidney function. Unfortunately, serum creatinine varies based on factors such as age, gender, and muscle mass. Overestimation of renal function by creatinine-based equations can be dangerous for renally dosed medications, such as enoxaparin. We present a patient who developed spontaneous bleeding on enoxaparin where kidney function was significantly overestimated by creatinine-based equations. The use of cystatin C levels, which are creatinine independent, can provide a better prediction of renal function.
- 2 January 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (1) , 131-133
Spontaneous bleeding in a patient on enoxaparin with poor renal function
Creatinine-based equations are used as standard ways to estimate glomerular filtration rate and kidney function. Unfortunately, serum creatinine varies based on factors such as age, gender, and muscle mass. Overestimation of renal function by creatinine-based equations can be dangerous for renally dosed medications, such as enoxaparin. We present a patient who developed spontaneous bleeding on enoxaparin where kidney function was significantly overestimated by creatinine-based equations. The use of cystatin C levels, which are creatinine independent, can provide a better prediction of renal function.
- 22 September 2017
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 354 (5) , 443-444
The Distribution of Plasma Electrolytes
- 22 September 2017
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 354 (5) , 443-444
The Distribution of Plasma Electrolytes
- 1 September 2017
- Published by Taylor & Francis in Hospital Practice
- Vol. 45 (5) , 192-195
Topiramate and metabolic acidosis: an evolving story
Topiramate is an anticonvulsant that is being increasingly used for a number of different off-label indications. Its inhibition of carbonic anhydrase isoenzymes can lead to metabolic acidosis, elevated urine pH, reduced urine citrate, and hypercalciuria, thereby creating a milieu that is ripe for calcium phosphate stone formation. In this review, we describe a case of topiramate-induced metabolic acidosis. We review the frequency of metabolic acidosis among children and adults, as well as the mechanism of hyperchloremic metabolic acidosis and renal tubular acidosis in topiramate users. Finally, we describe the long-term effects of topiramate-induced metabolic acidosis, including nephrolithiasis, nephrocalcinosis, and bone degradation. Patients who are prescribed topiramate should be carefully monitored for metabolic derangements, and they may benefit from alkali supplementation, or in extreme cases, discontinuation of the drug altogether.
- 1 September 2017
- Published by Taylor & Francis in Hospital Practice
- Vol. 45 (5) , 192-195
Topiramate and metabolic acidosis: an evolving story
Topiramate is an anticonvulsant that is being increasingly used for a number of different off-label indications. Its inhibition of carbonic anhydrase isoenzymes can lead to metabolic acidosis, elevated urine pH, reduced urine citrate, and hypercalciuria, thereby creating a milieu that is ripe for calcium phosphate stone formation. In this review, we describe a case of topiramate-induced metabolic acidosis. We review the frequency of metabolic acidosis among children and adults, as well as the mechanism of hyperchloremic metabolic acidosis and renal tubular acidosis in topiramate users. Finally, we describe the long-term effects of topiramate-induced metabolic acidosis, including nephrolithiasis, nephrocalcinosis, and bone degradation. Patients who are prescribed topiramate should be carefully monitored for metabolic derangements, and they may benefit from alkali supplementation, or in extreme cases, discontinuation of the drug altogether.